Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 605.26M | 577.32M | 531.74M | 503.23M | 402.00M |
Gross Profit | 182.56M | 176.96M | 171.28M | 166.73M | 128.91M |
EBITDA | 178.76M | 163.28M | 157.08M | 156.47M | 121.72M |
Net Income | 120.25M | 111.86M | 100.68M | 114.68M | 78.06M |
Balance Sheet | |||||
Total Assets | 1.92B | 1.68B | 1.38B | 1.30B | 710.88M |
Cash, Cash Equivalents and Short-Term Investments | 95.20M | 298.53M | 268.43M | 442.36M | 23.50M |
Total Debt | 290.00K | 401.00K | 691.00K | 20.86M | 107.55M |
Total Liabilities | 531.88M | 362.36M | 214.21M | 177.50M | 235.17M |
Stockholders Equity | 1.39B | 1.32B | 1.17B | 1.12B | 475.71M |
Cash Flow | |||||
Free Cash Flow | -138.30M | -18.54M | -49.76M | -19.66M | 45.53M |
Operating Cash Flow | 146.32M | 249.86M | 92.59M | 97.16M | 114.63M |
Investing Cash Flow | -148.88M | -170.81M | -63.17M | -469.13M | -69.31M |
Financing Cash Flow | -61.26M | 48.69M | -86.93M | 437.58M | -42.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | CHF5.58B | 41.60 | 10.07% | 1.14% | 17.34% | 18.15% | |
52 Neutral | $7.65B | 0.16 | -63.14% | 2.08% | 16.38% | 0.82% | |
― | CHF1.06B | 19.23 | 11.46% | 0.05% | ― | ― | |
― | $5.41B | 27.11 | 18.36% | 0.03% | ― | ― | |
― | $2.67B | 34.44 | 4.84% | <0.01% | ― | ― | |
77 Outperform | CHF4.34B | 23.89 | 2.62% | 4.67% | -35.91% | ||
62 Neutral | CHF817.52M | ― | ― | 3.15% | 62.88% |
Bachem Holding AG reported a strong financial performance in the first half of 2025, with group sales reaching CHF 313.0 million, marking a 30.2% increase compared to the previous year. The company also saw a significant rise in EBITDA to CHF 91.0 million, reflecting a 64.0% increase. Bachem is investing heavily in expanding its production capacity, with more than CHF 400 million planned for 2025, and aims for over CHF 1 billion in revenue by 2026. The expansion includes the development of a new production site in Sisslerfeld, Switzerland, and the continued enhancement of existing facilities. These strategic moves are expected to bolster Bachem’s market position and meet the growing demand for its products.
The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
Bachem mourns the loss of its founder, Dr. h.c. Peter Grogg, who passed away at 83. Grogg, who founded the company in 1971, was instrumental in transforming Bachem into a world leader in peptide synthesis, leaving a significant mark on the firm and Swiss economic history. His leadership spanned over three decades, during which he served as CEO and later as chairman of the board. The announcement highlights the deep impact Grogg had on Bachem’s operations and its standing in the industry.
The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.
Bachem Holding AG announced that its Annual General Meeting 2025 approved all proposals from the Board of Directors, including a dividend of CHF 0.85 per share, to be paid on May 7, 2025. The meeting also saw the re-election of the President and Board members, the election of Dr. Simone Wyss Fedele to the Board, and the approval of various financial and sustainability reports. Forvis Mazars SA was appointed as the auditor for 2025. This approval reflects strong shareholder support and positions Bachem for continued stability and growth in the pharmaceutical and biotech sectors.